BNP Paribas Financial Markets Has $550,000 Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

BNP Paribas Financial Markets reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 62.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,021 shares of the medical instruments supplier's stock after selling 99,370 shares during the quarter. BNP Paribas Financial Markets owned 0.15% of AngioDynamics worth $550,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in AngioDynamics during the fourth quarter valued at about $28,000. R Squared Ltd bought a new position in AngioDynamics during the fourth quarter worth $49,000. US Bancorp DE raised its stake in AngioDynamics by 1,938.0% during the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after acquiring an additional 6,376 shares during the period. Quinn Opportunity Partners LLC bought a new stake in AngioDynamics in the fourth quarter valued at $92,000. Finally, OneDigital Investment Advisors LLC increased its position in AngioDynamics by 14.0% in the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock valued at $111,000 after acquiring an additional 1,490 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Trading Up 2.8%

AngioDynamics stock traded up $0.26 on Tuesday, reaching $9.71. 353,910 shares of the stock were exchanged, compared to its average volume of 552,921. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50. The firm has a fifty day moving average price of $9.47 and a two-hundred day moving average price of $9.53. The stock has a market cap of $394.29 million, a PE ratio of -1.72 and a beta of 0.58.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.16. The firm had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company's revenue was down 4.3% on a year-over-year basis. Equities analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $16.00 target price (up from $15.00) on shares of AngioDynamics in a report on Monday, April 7th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.